secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-08-24T23:59:59+00:00
Accession:  0001193125-23-219580
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies receives FDA Fast Track Designation for TSHA-102 in Rett syndrome
--------------------------------------------------------------------------------

- FDA granted Fast Track Designation for TSHA-102, an AAV9 gene therapy for Rett syndrome.
- TSHA-102 also holds FDA Orphan Drug and Rare Pediatric Disease designations plus EU Orphan Drug.
- Phase 1/2 REVEAL adult trial ongoing in Canada; second adult patient expected in current quarter.
- FDA cleared IND for pediatric patients; first pediatric dose expected Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523219580/0001193125-23-219580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523219580/d454718d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-219580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer